A Phase IIa, Double-Blind, Mechanistic Study of GSK3196165 in Combination With Methotrexate Therapy in Subjects With Active Rheumatoid Arthritis Despite Treatment With DMARDs

Trial Profile

A Phase IIa, Double-Blind, Mechanistic Study of GSK3196165 in Combination With Methotrexate Therapy in Subjects With Active Rheumatoid Arthritis Despite Treatment With DMARDs

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Jul 2017

At a glance

  • Drugs GSK 3196165 (Primary) ; Folic acid; Methotrexate; Methotrexate
  • Indications Rheumatoid arthritis
  • Focus Biomarker; Pharmacodynamics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 12 Jul 2017 Planned End Date changed from 6 Oct 2017 to 19 Oct 2017.
    • 12 Jul 2017 Planned primary completion date changed from 1 May 2017 to 19 Oct 2017.
    • 12 Jul 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top